Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + anti-PSMA designer T cells
- Development stage
- Unknown
- Lead developer
- Roger Williams Medical Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Keytruda-Roger Williams Medical Center-prostate cancer refers to a combination therapy regimen consisting of the PD-1 checkpoint inhibitor pembrolizumab (Keytruda) and autologous anti-PSMA designer T cells. Developed at Roger Williams Medical Center, the designer T cells are a second-generation chimeric antigen receptor (CAR) T-cell therapy engineered to target Prostate-Specific Membrane Antigen (PSMA), a protein highly expressed on the surface of prostate cancer cells. Pembrolizumab is a monoclonal antibody that blocks the Programmed Cell Death Protein 1 (PD-1) receptor, thereby preventing the inhibition of T-cell activity. In this combination, pembrolizumab is utilized to potentially enhance the efficacy, persistence, and infiltration of the CAR-T cells by mitigating the immunosuppressive effects of the tumor microenvironment. This regimen has been investigated in Phase Ia/Ib clinical trials for patients with advanced, hormone-refractory (castration-resistant) prostate cancer.
- Brand names
- Keytruda
- Other names
- pembrolizumab + anti-PSMA CAR-T cellsKeytruda + anti-PSMA designer T cells
02
Targets
PSMA (Prostate-specific membrane antigen)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab + anti-PSMA designer T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + anti-PSMA designer T cells.